Presentation is loading. Please wait.

Presentation is loading. Please wait.

Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial.

Similar presentations


Presentation on theme: "Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial."— Presentation transcript:

1 Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90 by Alfred Reiter, Martin Schrappe, Markus Tiemann, Wolf-Dieter Ludwig, Elif Yakisan, Martin Zimmermann, Georg Mann, Andreas Chott, Wolfram Ebell, Thomas Klingebiel, Norbert Graf, Bernhard Kremens, Stefan Müller-Weihrich, Hans-Jürgen Plüss, Felix Zintl, Günter Henze, and Hansjörg Riehm Blood Volume 94(10): November 15, 1999 ©1999 by American Society of Hematology

2 Treatment strategy. Treatment strategy. Patients were stratified into 3 risk groups: R1, R2, and R3. The composition of therapy courses is given in Table 1. V, cytoreductive prophase; CR, complete response; SL-OP, second-look operation; ABMT, autologous BMT or blood stem cell transplantation. Alfred Reiter et al. Blood 1999;94: ©1999 by American Society of Hematology

3 Distribution of pretreatment serum LDH concentrations (logarithmic scale) according to stage of disease. Distribution of pretreatment serum LDH concentrations (logarithmic scale) according to stage of disease. (○) Patients surviving event-free; (□) toxic death; (▴) patients suffering from progress; (*) patients who developed second malignancy. From 16 patyients (2, 7, 2, 1, and 4 of stage I, II, III, IV, and B-ALL, respectively) the LDH values are lacking. One of these patients (stage IV) relapsed, and 2 B-ALL patients died of acute cell lysis syndrome. One patient (stage III) with LDH less than 100 U/L and 3 patients (B-ALL) with LDH greater than 10,000 are not depicted; 1 of them (B-ALL) died of acute cell lysis syndrome. Alfred Reiter et al. Blood 1999;94: ©1999 by American Society of Hematology

4 Alfred Reiter et al. Blood 1999;94:3294-3306
©1999 by American Society of Hematology

5 Alfred Reiter et al. Blood 1999;94:3294-3306
©1999 by American Society of Hematology

6 Kaplan-Meier estimate of EFS according to stage.
Kaplan-Meier estimate of EFS according to stage. SE, standard error. Alfred Reiter et al. Blood 1999;94: ©1999 by American Society of Hematology

7 Alfred Reiter et al. Blood 1999;94:3294-3306
©1999 by American Society of Hematology

8 Alfred Reiter et al. Blood 1999;94:3294-3306
©1999 by American Society of Hematology

9 Kaplan-Meier estimate of EFS for patients with abdominal stage III B-NHL and LDH ≥500 U/L in trial NHL-BFM 90 and in the preceding trial NHL-BFM 86. Kaplan-Meier estimate of EFS for patients with abdominal stage III B-NHL and LDH ≥500 U/L in trial NHL-BFM 90 and in the preceding trial NHL-BFM 86. SE, standard error. Alfred Reiter et al. Blood 1999;94: ©1999 by American Society of Hematology


Download ppt "Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial."

Similar presentations


Ads by Google